A 28-year-old woman with inflammatory arthritis takes leflunomide (a teratogen and potential weak enzyme inducer) and asks about contraception. What i...

Question

A 28-year-old woman with inflammatory arthritis takes leflunomide (a teratogen and potential weak enzyme inducer) and asks about contraception. What is the key consideration?

Accepted Answer

Leflunomide is teratogenic; highly effective contraception is essential. As it may have weak enzyme-inducing properties, LARC methods unaffected by enzyme inducers (Cu-IUD, LNG-IUS, or DMPA) are ideal

Answer

Any method is fine; leflunomide has no interaction

Answer

Only condoms are suitable

Answer

She must stop leflunomide before starting contraception

Answer

Leflunomide increases CHC efficacy

uk-dfsrh MCQ (SBA): Leflunomide Teratogen Weak Enzyme Inducer LARC

A 28-year-old woman with inflammatory arthritis takes leflunomide (a teratogen and potential weak enzyme inducer) and asks about contraception. What is the key consideration?